報價延遲最少15分鐘:2024/12/25 01:17 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
113.38 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
2.49/5.51
|
|
企業價值
2.16B
|
| 資產負債 |
|
每股賬面淨值
44.52
|
| 現金流量 |
|
現金流量率
0.04
|
| 損益表 |
|
收益
131.31M
|
|
每股收益
9.52
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/25 01:17 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license andmilestone payments, and sale of its trademarked Captisol material. |